Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mpt-0l055
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
MPT-Ol055 is an experimental small molecule drug. It is currently in the research phase and not approved for human or veterinary use. The compound has a chemical formula of C23H16ClN3O3 and a molecular weight of approximately 417.85 g/mol. Its mechanism of action and primary indication are not publicly disclosed in available sources[1][2][3].
- Other names
- 4-(((3-chloro-1,4-dihydro-1,4-dioxo-2-naphthalenyl)amino)methyl)-n-3-pyridinylbenzamide4-(((3-chloro-1,4-dioxo-1,4 dihydronaphthalen-2-yl)amino)methyl)-n-(pyridine-3-yl)benzamideBenzamide, 4-(((3-chloro-1,4-dihydro-1,4-dioxo-2-naphthalenyl)amino)methyl)-n-(pyridinium ylidene)MPT0L055MPT-0L055MPT 0L055
Beyond the preview
Go deeper on mpt-0l055.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mpt-0l055.